NZ529012A - Equine herpesvirus vaccine - Google Patents

Equine herpesvirus vaccine

Info

Publication number
NZ529012A
NZ529012A NZ529012A NZ52901202A NZ529012A NZ 529012 A NZ529012 A NZ 529012A NZ 529012 A NZ529012 A NZ 529012A NZ 52901202 A NZ52901202 A NZ 52901202A NZ 529012 A NZ529012 A NZ 529012A
Authority
NZ
New Zealand
Prior art keywords
ehv
vaccine
virus
inactivated
eiv
Prior art date
Application number
NZ529012A
Other languages
English (en)
Inventor
Mark W Mellencamp
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of NZ529012A publication Critical patent/NZ529012A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ529012A 2001-03-20 2002-01-23 Equine herpesvirus vaccine NZ529012A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/812,720 US6803041B2 (en) 2001-03-20 2001-03-20 Equine herpesvirus vaccine
PCT/US2002/001644 WO2002074335A2 (en) 2001-03-20 2002-01-23 Equine herpesvirus vaccine

Publications (1)

Publication Number Publication Date
NZ529012A true NZ529012A (en) 2005-08-26

Family

ID=25210428

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ529012A NZ529012A (en) 2001-03-20 2002-01-23 Equine herpesvirus vaccine

Country Status (15)

Country Link
US (3) US6803041B2 (enExample)
EP (2) EP1372712B1 (enExample)
JP (2) JP4177112B2 (enExample)
KR (1) KR100840525B1 (enExample)
AR (2) AR032984A1 (enExample)
AT (1) ATE392903T1 (enExample)
CA (1) CA2441292C (enExample)
CY (1) CY1108200T1 (enExample)
DE (1) DE60226218T2 (enExample)
DK (2) DK1372712T3 (enExample)
ES (2) ES2305220T3 (enExample)
MX (1) MXPA03008287A (enExample)
NZ (1) NZ529012A (enExample)
PT (1) PT1372712E (enExample)
WO (1) WO2002074335A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
BRPI0618041A2 (pt) * 2005-11-01 2011-08-16 Intervet Int Bv uso de um vìrus inativado da influenza eqüina, e, método para a proteção de eqüinos contra a infecção com influenza eqüina
US9642908B2 (en) 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
ES2675771T3 (es) 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
EP2569007B1 (en) * 2010-05-11 2015-10-14 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
ES2742325T3 (es) * 2013-05-14 2020-02-13 Zoetis Services Llc Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
CA3225885A1 (en) * 2021-08-06 2023-02-09 Sylvia REEMERS Vaccine for equine herpesvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4083958A (en) 1976-09-13 1978-04-11 The University Of Kentucky Research Foundation Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en) 1979-03-08 1980-09-30 The University Of Illinois Foundation Vaccine for equine rhinopneumonitis
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5084271B1 (en) 1984-09-11 1997-08-05 Univ Melbourne Vaccine for equine herpesvirus
US4758641A (en) 1987-02-24 1988-07-19 The B F Goodrich Company Polycarboxylic acids with small amount of residual monomer
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en) 1988-11-28 1993-06-22 The B. F. Goodrich Company Crosslinked polyacrylic acid
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US6025181A (en) * 1990-07-06 2000-02-15 University Court Of The University Of Glasgow Equine herpesvirus-4TK mutant
DE69131984T2 (de) 1990-08-01 2000-07-06 Research Corp. Technologies, Inc. Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
EP0532833A1 (en) 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
DE69333416D1 (de) 1992-06-01 2004-03-18 Univ Melbourne Parkville Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) * 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
JP2002504227A (ja) 1997-03-12 2002-02-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング クロマトグラフィーカラムの末端部材
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
EP0978286A1 (en) 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine

Also Published As

Publication number Publication date
AR091235A2 (es) 2015-01-21
DE60226218T2 (de) 2009-05-28
JP4668951B2 (ja) 2011-04-13
EP1372712A2 (en) 2004-01-02
WO2002074335A3 (en) 2003-07-17
DE60226218D1 (de) 2008-06-05
WO2002074335A2 (en) 2002-09-26
EP1923071A1 (en) 2008-05-21
JP2007197470A (ja) 2007-08-09
CA2441292C (en) 2012-03-20
EP1372712B1 (en) 2008-04-23
ATE392903T1 (de) 2008-05-15
US7226604B2 (en) 2007-06-05
AR032984A1 (es) 2003-12-03
MXPA03008287A (es) 2004-10-28
US20050084502A1 (en) 2005-04-21
US20070196390A1 (en) 2007-08-23
KR100840525B1 (ko) 2008-06-24
US6803041B2 (en) 2004-10-12
CY1108200T1 (el) 2014-02-12
PT1372712E (pt) 2008-05-29
CA2441292A1 (en) 2002-09-26
KR20030085028A (ko) 2003-11-01
DK1372712T3 (da) 2008-08-04
JP2004525923A (ja) 2004-08-26
JP4177112B2 (ja) 2008-11-05
EP1923071B1 (en) 2013-06-19
ES2305220T3 (es) 2008-11-01
ES2428664T3 (es) 2013-11-08
DK1923071T3 (da) 2013-08-26
US20030206924A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
US20070196390A1 (en) Equine herpesvirus vaccine
TWI320715B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
US20200093914A1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
US6372223B1 (en) Influenza virus vaccine composition
NZ566490A (en) Live attenuated or killed H3N8 influenza vaccines and methods to treat canine influenza
EP0329264A2 (en) Veterinary vaccines
US20030170251A1 (en) Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP1917031A1 (en) Lawsonia vaccine and methods of use thereof
IL296578A (en) Vaccine compositions for the treatment of coronavirus
US9585954B2 (en) Mucosal immunization
RU2553222C2 (ru) Композиции для лечения и предупреждения комплекса респираторных заболеваний собак
AU2002245287B2 (en) Equine herpesvirus vaccine
AU2002245287A1 (en) Equine herpesvirus vaccine
IL298288A (en) Methods of using hsv-2 single cycle virus delta-gd and hsv-2 recombinant glycoprotein d
IL293167A (en) Triple vaccine against Avibacterium paraglinarum, fowl pox virus and fowl pox virus
CN115141773A (zh) 牛支原体组合物
US20250302941A1 (en) Application of an Immunogenic or Vaccine Composition
US20250114447A1 (en) Vaccine for equine herpesvirus
WO2025157063A1 (zh) 猪流行性腹泻病毒s蛋白及相关产品
KR20140046143A (ko) 안약형 백신의 신규 아쥬반트
CN118005747A (zh) 非洲猪瘟病毒抗原表位、融合蛋白及其应用

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 23 JAN 2022 BY DENNEMEYER + CO

Effective date: 20140823

EXPY Patent expired